ATE518836T1 - Antagonisten des 5-ht7-rezeptors - Google Patents
Antagonisten des 5-ht7-rezeptorsInfo
- Publication number
- ATE518836T1 ATE518836T1 AT05820659T AT05820659T ATE518836T1 AT E518836 T1 ATE518836 T1 AT E518836T1 AT 05820659 T AT05820659 T AT 05820659T AT 05820659 T AT05820659 T AT 05820659T AT E518836 T1 ATE518836 T1 AT E518836T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor
- compounds
- antagonists
- acenaphthylen
- aza
- Prior art date
Links
- 108091005436 5-HT7 receptors Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- DERXXZAOHFJKSL-UHFFFAOYSA-N ac1nhds7 Chemical group C1CNC2CCC3=CC=CC1=C32 DERXXZAOHFJKSL-UHFFFAOYSA-N 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- -1 sulfonamide compounds Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04380280A EP1676840A1 (en) | 2004-12-28 | 2004-12-28 | 5-HT7 Receptor antagonists |
| US11/048,991 US20060142321A1 (en) | 2004-12-28 | 2005-02-02 | 5-HT7 receptor antagonists |
| PCT/EP2005/014044 WO2006069775A1 (en) | 2004-12-28 | 2005-12-27 | 5-ht7 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE518836T1 true ATE518836T1 (de) | 2011-08-15 |
Family
ID=34931895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05820659T ATE518836T1 (de) | 2004-12-28 | 2005-12-27 | Antagonisten des 5-ht7-rezeptors |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20060142321A1 (enExample) |
| EP (2) | EP1676840A1 (enExample) |
| JP (1) | JP2008525512A (enExample) |
| KR (1) | KR20070098882A (enExample) |
| CN (1) | CN101389608A (enExample) |
| AT (1) | ATE518836T1 (enExample) |
| AU (1) | AU2005321462A1 (enExample) |
| BR (1) | BRPI0519788A2 (enExample) |
| CA (1) | CA2591201A1 (enExample) |
| ES (1) | ES2370877T3 (enExample) |
| MX (1) | MX2007007893A (enExample) |
| RU (1) | RU2007128964A (enExample) |
| WO (1) | WO2006069775A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1875899A1 (en) * | 2006-06-29 | 2008-01-09 | Laboratorios Del Dr. Esteve, S.A. | Use of 5HT7 receptor agonists for the treatment of pain |
| WO2012058769A1 (en) * | 2010-11-03 | 2012-05-10 | Mcmaster University | Method of treating mucosal inflammation |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ193654A (en) | 1979-05-16 | 1984-08-24 | Wuelfing Johann A | Naphthalene sulphonamido-alkyl-piperidines,pyrrolidines or piperazines and pharmaceutical compositions |
| DE3276313D1 (en) | 1981-09-24 | 1987-06-19 | Beecham Wuelfing Gmbh & Co Kg | Sulphonamides |
| JP2000504677A (ja) | 1996-02-09 | 2000-04-18 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ５ｈｔ７レセプター・アンタゴニスト用のスルホンアミド誘導体 |
| GB9612884D0 (en) | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
| EP0912550A1 (en) * | 1996-06-25 | 1999-05-06 | Smithkline Beecham Plc | Sulfonamide derivatives as 5ht7 receptor antagonists |
| ATE296801T1 (de) | 1996-06-28 | 2005-06-15 | Meiji Seika Kaisha | Tetrahydrobezindol derivate |
| AU1558899A (en) | 1997-11-10 | 1999-05-31 | F. Hoffmann-La Roche Ag | Isoquinoline derivatives for use against cns disorders |
| AU4698299A (en) * | 1998-06-30 | 2000-01-17 | Du Pont Pharmaceuticals Company | 5-HT7 receptor antagonists |
| GB0128885D0 (en) | 2001-12-03 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
-
2004
- 2004-12-28 EP EP04380280A patent/EP1676840A1/en not_active Withdrawn
-
2005
- 2005-02-02 US US11/048,991 patent/US20060142321A1/en not_active Abandoned
- 2005-12-27 MX MX2007007893A patent/MX2007007893A/es not_active Application Discontinuation
- 2005-12-27 ES ES05820659T patent/ES2370877T3/es active Active
- 2005-12-27 CN CNA2005800452313A patent/CN101389608A/zh active Pending
- 2005-12-27 CA CA002591201A patent/CA2591201A1/en not_active Abandoned
- 2005-12-27 WO PCT/EP2005/014044 patent/WO2006069775A1/en not_active Ceased
- 2005-12-27 BR BRPI0519788-0A patent/BRPI0519788A2/pt not_active IP Right Cessation
- 2005-12-27 EP EP05820659A patent/EP1836172B1/en not_active Not-in-force
- 2005-12-27 AU AU2005321462A patent/AU2005321462A1/en not_active Abandoned
- 2005-12-27 KR KR1020077017188A patent/KR20070098882A/ko not_active Withdrawn
- 2005-12-27 RU RU2007128964/04A patent/RU2007128964A/ru not_active Application Discontinuation
- 2005-12-27 JP JP2007548746A patent/JP2008525512A/ja active Pending
- 2005-12-27 AT AT05820659T patent/ATE518836T1/de not_active IP Right Cessation
-
2009
- 2009-05-22 US US12/471,128 patent/US7662862B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007007893A (es) | 2007-10-03 |
| KR20070098882A (ko) | 2007-10-05 |
| EP1836172B1 (en) | 2011-08-03 |
| US7662862B2 (en) | 2010-02-16 |
| JP2008525512A (ja) | 2008-07-17 |
| US20060142321A1 (en) | 2006-06-29 |
| EP1676840A1 (en) | 2006-07-05 |
| AU2005321462A1 (en) | 2006-07-06 |
| CN101389608A (zh) | 2009-03-18 |
| RU2007128964A (ru) | 2009-02-10 |
| US20090264458A1 (en) | 2009-10-22 |
| CA2591201A1 (en) | 2006-07-06 |
| WO2006069775A1 (en) | 2006-07-06 |
| EP1836172A1 (en) | 2007-09-26 |
| ES2370877T3 (es) | 2011-12-23 |
| BRPI0519788A2 (pt) | 2009-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003028641A3 (en) | Mch receptor antagonists | |
| DE602005020655D1 (de) | Carboxamid-spirolactam-cgrp-rezeptor-antagonisten | |
| NO20072435L (no) | CGRP-reseptorantagonister | |
| DE60229530D1 (de) | Substituierte piperazine als modulatoren des melanocortinrezeptors | |
| ATE493412T1 (de) | Spirohydantoin-aryl-cgrp-rezeptorantagonisten | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| EP1605936A4 (en) | ARYL-spiro hydantoin-CGRP Receptor Antagonists | |
| ATE485269T1 (de) | C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden | |
| ATE537170T1 (de) | Cgrp-rezeptorantagonisten | |
| JO2355B1 (en) | Hereditary calcitonin polypeptide receptor antagonists | |
| DE602004013563D1 (de) | Rantagonisten | |
| NO20092470L (no) | Substituerte diazepanforbindelser som orexinreseptorantagonister | |
| EA200700035A1 (ru) | Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders | |
| ATE293448T1 (de) | Benzo(d)azepin-derivative als 5-ht6-rezeptor- antagonisten | |
| EP1794133A4 (en) | ARYL SPIROLACTAM COMPOUNDS AS ANTAGONISTS OF THE CGRP RECEPTOR | |
| WO2006047196A3 (en) | Cgrp receptor antagonists | |
| MX2007002393A (es) | Compuestos indolicos sustituidos y su uso como moduladores del receptor de 5-hidroxitriptamina 6 (5-ht6). | |
| WO2007067511A3 (en) | Morpholine carboxamide prokineticin receptor antagonists | |
| WO2006038006A3 (en) | 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders | |
| WO2007019234A3 (en) | Aminoethane sulfonamide orexin receptor antagonists | |
| BRPI0519792A2 (pt) | antagonistas do receptor 5-ht7 | |
| MX2007001992A (es) | Antagonistas del receptor 5-ht7. | |
| ATE507880T1 (de) | Cgrp-rezeptorantagonisten | |
| MX2007001990A (es) | Antagonistas del receptor 5-ht7. | |
| DE602007004327D1 (de) | Einen azepin-kern enthaltende antagonisten des histaminrezeptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |